JP7632835B2 - 加齢関連疾患及び症状の遺伝子治療法 - Google Patents
加齢関連疾患及び症状の遺伝子治療法 Download PDFInfo
- Publication number
- JP7632835B2 JP7632835B2 JP2018560974A JP2018560974A JP7632835B2 JP 7632835 B2 JP7632835 B2 JP 7632835B2 JP 2018560974 A JP2018560974 A JP 2018560974A JP 2018560974 A JP2018560974 A JP 2018560974A JP 7632835 B2 JP7632835 B2 JP 7632835B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- protein
- promoter
- acid sequence
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001415 gene therapy Methods 0.000 title description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 81
- 201000010099 disease Diseases 0.000 title description 75
- 150000007523 nucleic acids Chemical group 0.000 claims description 380
- 108090000623 proteins and genes Proteins 0.000 claims description 370
- 239000013603 viral vector Substances 0.000 claims description 280
- 102000004169 proteins and genes Human genes 0.000 claims description 225
- 230000014509 gene expression Effects 0.000 claims description 191
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 178
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 101
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 101
- 230000001105 regulatory effect Effects 0.000 claims description 90
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 61
- 210000004962 mammalian cell Anatomy 0.000 claims description 48
- 230000027455 binding Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 230000008488 polyadenylation Effects 0.000 claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 30
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 25
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims description 22
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 241000282465 Canis Species 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 20
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 claims description 16
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 claims description 16
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 15
- 241000283073 Equus caballus Species 0.000 claims description 12
- 241000282324 Felis Species 0.000 claims description 10
- 241001529936 Murinae Species 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 8
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 8
- 108010044091 Globulins Proteins 0.000 claims description 8
- 102000006395 Globulins Human genes 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 101000930477 Mus musculus Albumin Proteins 0.000 claims description 8
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 8
- 239000005495 thyroid hormone Substances 0.000 claims description 8
- 229940036555 thyroid hormone Drugs 0.000 claims description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 3
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 description 164
- 102000039446 nucleic acids Human genes 0.000 description 159
- 108020004707 nucleic acids Proteins 0.000 description 159
- 241000700605 Viruses Species 0.000 description 151
- 210000004027 cell Anatomy 0.000 description 123
- 239000013598 vector Substances 0.000 description 98
- 241000124008 Mammalia Species 0.000 description 95
- 210000001519 tissue Anatomy 0.000 description 89
- -1 genes Chemical class 0.000 description 82
- 241000702421 Dependoparvovirus Species 0.000 description 76
- 102000015834 Klotho Human genes 0.000 description 68
- 108050004036 Klotho Proteins 0.000 description 68
- 230000002401 inhibitory effect Effects 0.000 description 62
- 239000002679 microRNA Substances 0.000 description 60
- 241001465754 Metazoa Species 0.000 description 55
- 230000003612 virological effect Effects 0.000 description 55
- 230000000694 effects Effects 0.000 description 51
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 49
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 47
- 101150113376 coq7 gene Proteins 0.000 description 45
- 101150016058 Ctf1 gene Proteins 0.000 description 44
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 44
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 44
- 108091070501 miRNA Proteins 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 43
- 108091033409 CRISPR Proteins 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 42
- 239000013604 expression vector Substances 0.000 description 42
- 108020005004 Guide RNA Proteins 0.000 description 38
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 37
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 37
- 101150057269 IKBKB gene Proteins 0.000 description 34
- 102000011690 Adiponectin Human genes 0.000 description 33
- 108010076365 Adiponectin Proteins 0.000 description 33
- 101710163270 Nuclease Proteins 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 101000794231 Mus musculus Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Proteins 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 239000013607 AAV vector Substances 0.000 description 27
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 27
- 101150118107 SLC13A5 gene Proteins 0.000 description 27
- 102000008347 Sodium Sulfate Cotransporter Human genes 0.000 description 26
- 108010021572 Sodium Sulfate Cotransporter Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 101150109526 Sirt6 gene Proteins 0.000 description 23
- 238000012384 transportation and delivery Methods 0.000 description 23
- 101150061566 ADRA1A gene Proteins 0.000 description 22
- 101150018308 Adra1d gene Proteins 0.000 description 22
- 101100490687 Mus musculus Agtr1a gene Proteins 0.000 description 22
- 101150096483 atg5 gene Proteins 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 21
- 101150101745 F2rl3 gene Proteins 0.000 description 21
- 208000008589 Obesity Diseases 0.000 description 21
- 101150114311 PAWR gene Proteins 0.000 description 21
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 21
- 101150061874 TXN gene Proteins 0.000 description 21
- 235000020824 obesity Nutrition 0.000 description 21
- 230000002103 transcriptional effect Effects 0.000 description 21
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 20
- 101150042222 DGAT1 gene Proteins 0.000 description 20
- 241000125945 Protoparvovirus Species 0.000 description 20
- 230000032683 aging Effects 0.000 description 19
- 101150045355 akt1 gene Proteins 0.000 description 19
- 230000028327 secretion Effects 0.000 description 19
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 18
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 18
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 18
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 18
- 101000837841 Homo sapiens Transcription factor EB Proteins 0.000 description 18
- 102100028502 Transcription factor EB Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 17
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 17
- 101150039326 PCK1 gene Proteins 0.000 description 17
- 101150061984 Adcy5 gene Proteins 0.000 description 16
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 16
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 16
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 16
- 241000649045 Adeno-associated virus 10 Species 0.000 description 16
- 241000649047 Adeno-associated virus 12 Species 0.000 description 16
- 101150013665 MT1 gene Proteins 0.000 description 16
- 101150076245 Rps6kb1 gene Proteins 0.000 description 16
- 238000001476 gene delivery Methods 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 15
- 241000649046 Adeno-associated virus 11 Species 0.000 description 15
- 101150059488 NUDT1 gene Proteins 0.000 description 15
- 101150079815 Sema3a gene Proteins 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 15
- 108091033319 polynucleotide Proteins 0.000 description 15
- 239000002157 polynucleotide Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 210000002845 virion Anatomy 0.000 description 15
- 101150026325 CISD2 gene Proteins 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000004055 small Interfering RNA Substances 0.000 description 14
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 13
- 102000000344 Sirtuin 1 Human genes 0.000 description 13
- 108010041191 Sirtuin 1 Proteins 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 12
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 12
- 101100173048 Mus musculus Mcat gene Proteins 0.000 description 12
- 101100189360 Mus musculus Pappa gene Proteins 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 12
- 108091027967 Small hairpin RNA Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 108091007428 primary miRNA Proteins 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 101710096438 DNA-binding protein Proteins 0.000 description 11
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 11
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 101800000638 p2A Proteins 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 description 10
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 description 10
- 101150026109 INSR gene Proteins 0.000 description 10
- 101150004273 Prkar2b gene Proteins 0.000 description 10
- 102100028760 Sialidase-1 Human genes 0.000 description 10
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 230000004580 weight loss Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000001638 lipofection Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- GCSZJMUFYOAHFY-SDQBBNPISA-N (1z)-1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(O)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 GCSZJMUFYOAHFY-SDQBBNPISA-N 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 8
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 239000013608 rAAV vector Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101001034434 Homo sapiens Glutathione S-transferase kappa 1 Proteins 0.000 description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229960004359 iodixanol Drugs 0.000 description 7
- 108091026501 miR-122a stem-loop Proteins 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100039651 Glutathione S-transferase kappa 1 Human genes 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 5
- 208000031448 Genomic Instability Diseases 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 5
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 5
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 5
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 5
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 5
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 5
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 229940118764 francisella tularensis Drugs 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000013609 scAAV vector Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- SVDVJBWDBYSQLO-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-5-phenylimidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 SVDVJBWDBYSQLO-UHFFFAOYSA-N 0.000 description 4
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 4
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 4
- 102100022166 E3 ubiquitin-protein ligase NEURL1 Human genes 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 4
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 4
- 108020005196 Mitochondrial DNA Proteins 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 101150024252 Neu1 gene Proteins 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 4
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 108091005735 TGF-beta receptors Proteins 0.000 description 4
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 4
- 101150039242 Ubd gene Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000020934 caloric restriction Nutrition 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000004898 mitochondrial function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 101150061453 Cebpa gene Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 3
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 108091035664 Mirtron Proteins 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 241001442654 Percnon planissimum Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 108010057163 Ribonuclease III Proteins 0.000 description 3
- 102000003661 Ribonuclease III Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 101150004620 Cebpb gene Proteins 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 102000047351 Exportin-5 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091081406 G-quadruplex Proteins 0.000 description 2
- 241000423296 Gluconacetobacter diazotrophicus PA1 5 Species 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108091093094 Glycol nucleic acid Proteins 0.000 description 2
- 101150027313 Has2 gene Proteins 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 2
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 101150094724 PCSK9 gene Proteins 0.000 description 2
- 241000121250 Parvovirinae Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004792 Prolene Substances 0.000 description 2
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 2
- 238000010357 RNA editing Methods 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241001313536 Thermothelomyces thermophila Species 0.000 description 2
- 108091046915 Threose nucleic acid Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000005101 cell tropism Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000009063 long-term regulation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091007426 microRNA precursor Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003955 neuronal function Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 241000417230 Actinobacillus succinogenes 130Z Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000257169 Bacillus cereus ATCC 10987 Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000586987 Bifidobacterium dentium Bd1 Species 0.000 description 1
- 241001209261 Bifidobacterium longum DJO10A Species 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 241001453247 Campylobacter jejuni subsp. doylei Species 0.000 description 1
- 241000941427 Campylobacter lari RM2100 Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241001034636 Capnocytophaga ochracea DSM 7271 Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001509423 Clostridium botulinum B Species 0.000 description 1
- 241001509504 Clostridium botulinum F Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000671338 Corynebacterium glutamicum R Species 0.000 description 1
- 241001525611 Corynebacterium kroppenstedtii DSM 44385 Species 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100402804 Danio rerio mt gene Proteins 0.000 description 1
- 241000121256 Densovirinae Species 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 241000688137 Diaphorobacter Species 0.000 description 1
- 241000933091 Dinoroseobacter shibae DFL 12 = DSM 16493 Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000448576 Elusimicrobium minutum Pei191 Species 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000608038 Fibrobacter succinogenes subsp. succinogenes S85 Species 0.000 description 1
- 241000359186 Finegoldia magna ATCC 29328 Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101100120063 Homo sapiens FGF21 gene Proteins 0.000 description 1
- 101000617805 Homo sapiens Staphylococcal nuclease domain-containing protein 1 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- 241001596092 Kribbella flavida DSM 17836 Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241001193656 Legionella pneumophila str. Paris Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001378931 Methanococcus maripaludis C7 Species 0.000 description 1
- 241000825684 Mycobacterium abscessus ATCC 19977 Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000107400 Mycoplasma mobile 163K Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000051161 Mycoplasma synoviae 53 Species 0.000 description 1
- 101150094238 NFE2 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241001648684 Nitrobacter hamburgensis X14 Species 0.000 description 1
- 241001037736 Nocardia farcinica IFM 10152 Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000601272 Parvibaculum lavamentivorans DS-1 Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 241000549884 Persephonella marina EX-H1 Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 241000773205 Pseudarthrobacter chlorophenolicus A6 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000647111 Rhodococcus erythropolis PR4 Species 0.000 description 1
- 241001303434 Rhodopseudomonas palustris BisB18 Species 0.000 description 1
- 241001303431 Rhodopseudomonas palustris BisB5 Species 0.000 description 1
- 241000134686 Rhodospirillum rubrum ATCC 11170 Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000516659 Roseiflexus Species 0.000 description 1
- 241000504328 Roseiflexus castenholzii DSM 13941 Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 241000863430 Shewanella Species 0.000 description 1
- 241000977068 Simian Adeno-associated virus Species 0.000 description 1
- 241001496704 Slackia heliotrinireducens DSM 20476 Species 0.000 description 1
- 102100021996 Staphylococcal nuclease domain-containing protein 1 Human genes 0.000 description 1
- 241000756832 Streptobacillus moniliformis DSM 12112 Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001209210 Streptococcus agalactiae A909 Species 0.000 description 1
- 241001540742 Streptococcus agalactiae NEM316 Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241001167808 Streptococcus gallolyticus UCN34 Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000672607 Streptococcus mutans NN2025 Species 0.000 description 1
- 241000320123 Streptococcus pyogenes M1 GAS Species 0.000 description 1
- 241000103155 Streptococcus pyogenes MGAS10270 Species 0.000 description 1
- 241000103160 Streptococcus pyogenes MGAS10750 Species 0.000 description 1
- 241000103154 Streptococcus pyogenes MGAS2096 Species 0.000 description 1
- 241001520169 Streptococcus pyogenes MGAS315 Species 0.000 description 1
- 241001148739 Streptococcus pyogenes MGAS5005 Species 0.000 description 1
- 241001332083 Streptococcus pyogenes MGAS6180 Species 0.000 description 1
- 241000103156 Streptococcus pyogenes MGAS9429 Species 0.000 description 1
- 241001496716 Streptococcus pyogenes NZ131 Species 0.000 description 1
- 241001455236 Streptococcus pyogenes SSI-1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 241001496699 Thermomonospora curvata DSM 43183 Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 241000999858 Treponema denticola ATCC 35405 Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000847071 Verminephrobacter eiseniae EF01-2 Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000605941 Wolinella Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000883281 [Clostridium] cellulolyticum H10 Species 0.000 description 1
- 241000714896 [Eubacterium] rectale ATCC 33656 Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000007172 age related pathology Effects 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000057799 human ADIPOQ Human genes 0.000 description 1
- 102000052734 human GSTK1 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical compound [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 108091057414 miR-376 stem-loop Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000019569 negative regulation of cell differentiation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000032312 synaptic target recognition Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 241001496653 uncultured Termite group 1 bacterium phylotype Rs-D17 Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194601A JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339182P | 2016-05-20 | 2016-05-20 | |
| US62/339,182 | 2016-05-20 | ||
| US201662421665P | 2016-11-14 | 2016-11-14 | |
| US62/421,665 | 2016-11-14 | ||
| PCT/US2017/033815 WO2017201527A2 (en) | 2016-05-20 | 2017-05-22 | Gene therapy methods for age-related diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Division JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519221A JP2019519221A (ja) | 2019-07-11 |
| JP2019519221A5 JP2019519221A5 (enExample) | 2020-08-27 |
| JP7632835B2 true JP7632835B2 (ja) | 2025-02-19 |
Family
ID=60326179
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560974A Active JP7632835B2 (ja) | 2016-05-20 | 2017-05-22 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12281154B2 (enExample) |
| EP (1) | EP3458585A4 (enExample) |
| JP (4) | JP7632835B2 (enExample) |
| CN (2) | CN109844124B (enExample) |
| AU (2) | AU2017268469C1 (enExample) |
| BR (1) | BR112018073861A2 (enExample) |
| CA (1) | CA3025020A1 (enExample) |
| MX (3) | MX2018014256A (enExample) |
| WO (1) | WO2017201527A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110494151A (zh) * | 2017-02-14 | 2019-11-22 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Naf-1衍生肽及其用途 |
| KR102616820B1 (ko) * | 2017-03-17 | 2023-12-21 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 향상된 유전자 발현을 위한 조성물 및 방법 |
| BR112019024608A2 (pt) * | 2017-05-24 | 2020-06-23 | Universitat Autonoma De Barcelona | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
| KR102765034B1 (ko) | 2017-05-24 | 2025-02-11 | 유니버시타트 아우토노마 데 바르셀로나 | 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트 |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| JP7330517B2 (ja) * | 2017-10-20 | 2023-08-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 異種タンパク質産生のための人工分泌ペプチド |
| US11807850B2 (en) | 2017-12-06 | 2023-11-07 | Klogenix Llc | Compositions and methods for modulating gene expression |
| SG11202101819QA (en) * | 2018-08-30 | 2021-03-30 | Res Inst Nationwide Childrens Hospital | Gene therapy for the treatment of galactosemia |
| EP3866842A4 (en) * | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| US12134772B2 (en) | 2018-11-21 | 2024-11-05 | Advantage Therapeutics, Inc. | Increasing gene expression |
| IL283452B2 (en) * | 2018-11-26 | 2026-04-01 | Univ Barcelona Autonoma | FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY |
| US12203070B2 (en) | 2019-05-23 | 2025-01-21 | Christiana Care Gene Editing Institute, Inc. | Gene knockout of NRF2 for treatment of cancer |
| JP7585237B2 (ja) | 2019-05-23 | 2024-11-18 | クリスティアナ ケア ジーン エディティング インスティテュート，インコーポレーテッド | がんを処置するためのバリアントｎｒｆ２の遺伝子ノックアウト |
| US20230038502A1 (en) | 2019-06-11 | 2023-02-09 | Shire Human Genetic Therapies, Inc. | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| US10653731B1 (en) * | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| KR102281858B1 (ko) | 2019-09-11 | 2021-07-26 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물 |
| CN114555814A (zh) * | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
| WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN110894508B (zh) * | 2019-10-31 | 2021-08-06 | 内蒙古大学 | 一种调控白色脂肪棕色化的基因Adra1a的应用 |
| US12673089B2 (en) | 2019-12-05 | 2026-07-07 | President And Fellows Of Harvard College | Methods for treating osteoarthritis |
| JP7588466B2 (ja) * | 2020-01-22 | 2024-11-22 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| EP4142758A4 (en) * | 2020-04-28 | 2025-02-26 | President and Fellows of Harvard College | High efficiency gene delivery system |
| JP2023526049A (ja) * | 2020-05-13 | 2023-06-20 | リソジェン | Ｇｍ１ガングリオシド－シスおよび他の障害を処置するための組成物および方法 |
| CN115916985A (zh) * | 2020-05-26 | 2023-04-04 | 巴塞罗那自治大学 | 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法 |
| CN114181944B (zh) * | 2020-09-14 | 2023-10-03 | 中国科学院动物研究所 | 突变基因及构建短肢性侏儒症小型猪模型的方法和用途 |
| WO2022115739A2 (en) * | 2020-11-30 | 2022-06-02 | Cellular Longevity, Inc. | Lnp and liposome compositions for longevity in mammals and methods of using the same |
| EP4263614A1 (en) | 2020-12-16 | 2023-10-25 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| KR102590276B1 (ko) * | 2021-01-04 | 2023-10-16 | 부산대학교 산학협력단 | 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도 |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| CN113088531B (zh) * | 2021-03-25 | 2023-10-17 | 四川省药品检验研究院(四川省医疗器械检测中心) | 牛源性成分定量分析标准质粒、制备及检测方法及应用 |
| WO2022221291A2 (en) * | 2021-04-12 | 2022-10-20 | University Of Florida Research Foundation Incorporated | Compositions and methods for treating obesity |
| JP2022169389A (ja) * | 2021-04-27 | 2022-11-09 | 国立大学法人北海道大学 | イヌＴＧＦ－β受容体ＩＩ |
| US12564646B2 (en) * | 2021-06-16 | 2026-03-03 | BioViva USA, Inc. | Treatment of age-related cognitive decline using genetically modified viral vectors |
| US20230018934A1 (en) * | 2021-07-16 | 2023-01-19 | Genflow Biosciences Srl | Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus |
| US20240384245A1 (en) * | 2021-09-29 | 2024-11-21 | Sirt6 Ltd | Method for treating a disease |
| CN114921480A (zh) * | 2022-06-09 | 2022-08-19 | 国科宁波生命与健康产业研究院 | 一种骨细胞Terc基因敲除小鼠模型的构建方法 |
| WO2024064785A2 (en) * | 2022-09-21 | 2024-03-28 | Rejuvenate Bio | Gene therapy methods for familial partial lipodystrophy |
| US20260102513A1 (en) * | 2022-09-21 | 2026-04-16 | Rejuvenate Bio | Gene therapy methods for arrhythmogenic cardiomyopathy |
| EP4590693A2 (en) * | 2022-09-21 | 2025-07-30 | Rejuvenate Bio Inc | Gene therapy methods for treating mitral valve disease |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
| EP4566618A1 (en) * | 2023-12-06 | 2025-06-11 | ADvantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
| WO2025109173A1 (en) | 2023-11-22 | 2025-05-30 | Advantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
| CN119920318B (zh) * | 2024-03-07 | 2026-05-15 | 深圳华大生命科学研究院 | 复杂疾病功能特异的核心标记物构建方法及相关设备 |
| WO2026002276A1 (zh) * | 2024-06-28 | 2026-01-02 | 艾码生物科技(南京)有限公司 | 靶向tgfb的rna干扰方法、核酸及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| JP2009532025A (ja) | 2006-03-31 | 2009-09-10 | セル ジェネシス インコーポレイテッド | アデノ関連ウイルスベクターからの組換えタンパク質の制御された発現 |
| JP2014526441A (ja) | 2011-08-31 | 2014-10-06 | アムジエン・インコーポレーテツド | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| US7622300B2 (en) * | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
| US7419829B2 (en) * | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| AU2003209226A1 (en) | 2002-01-11 | 2003-07-30 | Michael Tennant | Adiponectin gene therapy |
| US8158589B2 (en) * | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| WO2006052568A2 (en) * | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| PL1874818T3 (pl) * | 2005-04-22 | 2011-09-30 | Lilly Co Eli | Przeciwciała swoiste wobec TGF-beta 1 |
| DE102005061840A1 (de) * | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
| NZ575804A (en) | 2006-09-13 | 2012-01-12 | Univ Columbia | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| JP2010529859A (ja) * | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質 |
| US8236557B2 (en) * | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| AR083445A1 (es) * | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| ES2423798T3 (es) * | 2010-11-19 | 2013-09-24 | Universitätsklinikum Freiburg | Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| JO3476B1 (ar) * | 2011-09-26 | 2020-07-05 | Novartis Ag | بروتينات مندمجة لعلاج الاضطرابات الايضية |
| TWI614031B (zh) | 2011-11-03 | 2018-02-11 | 國立陽明大學 | 防止皮膚老化相關症狀的醫藥組合物及其使用方法 |
| WO2013111081A1 (en) | 2012-01-24 | 2013-08-01 | Bar-Ilan University | Treatment of disease by modulation of sirt6 |
| CN103665166A (zh) * | 2012-09-03 | 2014-03-26 | 福又达生物科技股份有限公司 | 犬融合干扰素 |
| WO2014152993A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Regents Of The University Of Oklahoma | Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| US10227394B2 (en) * | 2014-04-08 | 2019-03-12 | University Of Southern California | Polypeptide compositions with type VII collagen fibronectin type III-like repeats and treatment methods for wound closure and healing |
| KR20150135148A (ko) * | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| MX2017004947A (es) * | 2014-10-24 | 2017-06-29 | Bristol Myers Squibb Co | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017024407A1 (en) * | 2015-08-11 | 2017-02-16 | The Royal Institution For The Advancement Of Learning/Mcgill University | Peptidic tgf-beta antagonists |
-
2017
- 2017-05-22 CN CN201780058862.1A patent/CN109844124B/zh active Active
- 2017-05-22 CA CA3025020A patent/CA3025020A1/en active Pending
- 2017-05-22 EP EP17800329.9A patent/EP3458585A4/en active Pending
- 2017-05-22 JP JP2018560974A patent/JP7632835B2/ja active Active
- 2017-05-22 WO PCT/US2017/033815 patent/WO2017201527A2/en not_active Ceased
- 2017-05-22 CN CN202311189446.9A patent/CN117535350A/zh active Pending
- 2017-05-22 MX MX2018014256A patent/MX2018014256A/es unknown
- 2017-05-22 US US16/302,865 patent/US12281154B2/en active Active
- 2017-05-22 AU AU2017268469A patent/AU2017268469C1/en active Active
- 2017-05-22 BR BR112018073861-1A patent/BR112018073861A2/pt active Search and Examination
-
2018
- 2018-11-20 MX MX2022000085A patent/MX2022000085A/es unknown
- 2018-11-20 MX MX2025014039A patent/MX2025014039A/es unknown
-
2021
- 2021-11-30 JP JP2021194601A patent/JP7315284B2/ja active Active
-
2023
- 2023-03-20 JP JP2023044658A patent/JP2023078338A/ja active Pending
-
2024
- 2024-09-23 AU AU2024219991A patent/AU2024219991A1/en active Pending
- 2024-11-11 US US18/942,898 patent/US20250122267A1/en active Pending
-
2025
- 2025-02-25 JP JP2025028446A patent/JP2025078652A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| JP2009532025A (ja) | 2006-03-31 | 2009-09-10 | セル ジェネシス インコーポレイテッド | アデノ関連ウイルスベクターからの組換えタンパク質の制御された発現 |
| JP2014526441A (ja) | 2011-08-31 | 2014-10-06 | アムジエン・インコーポレーテツド | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Non-Patent Citations (2)
| Title |
|---|
| Ａｎｎｕ Ｒｅｖ Ｐｈｙｓｉｏｌ， ２０１６， ｖｏｌ．７８， ｐ．２２３－２４１ |
| ウイルス（１９９７）， ｖｏｌ．４７， ｐ２２１－２３０ |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190345224A1 (en) | 2019-11-14 |
| AU2017268469C1 (en) | 2025-01-02 |
| US12281154B2 (en) | 2025-04-22 |
| JP2019519221A (ja) | 2019-07-11 |
| MX2018014256A (es) | 2019-08-16 |
| MX2022000085A (es) | 2022-02-10 |
| CN109844124B (zh) | 2023-10-03 |
| CA3025020A1 (en) | 2017-11-23 |
| AU2017268469A1 (en) | 2019-01-03 |
| MX2025014039A (es) | 2026-01-07 |
| BR112018073861A2 (pt) | 2019-02-26 |
| WO2017201527A2 (en) | 2017-11-23 |
| AU2017268469B2 (en) | 2024-07-25 |
| CN117535350A (zh) | 2024-02-09 |
| JP2023078338A (ja) | 2023-06-06 |
| AU2024219991A1 (en) | 2024-10-10 |
| JP7315284B2 (ja) | 2023-07-26 |
| JP2025078652A (ja) | 2025-05-20 |
| WO2017201527A3 (en) | 2018-02-08 |
| EP3458585A2 (en) | 2019-03-27 |
| US20250122267A1 (en) | 2025-04-17 |
| JP2022033855A (ja) | 2022-03-02 |
| EP3458585A4 (en) | 2019-10-30 |
| CN109844124A (zh) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7315284B2 (ja) | 加齢関連疾患及び症状の遺伝子治療法 | |
| US11834474B2 (en) | AAV's and uses thereof | |
| US11826434B2 (en) | Isolation of novel AAV's and uses thereof | |
| US20190389934A1 (en) | Heterologous targeting peptide grafted aavs | |
| AU2017227776C1 (en) | AAV vectors for treatment of dominant retinitis pigmentosa | |
| CN113710693B (zh) | Dna结合结构域反式激活因子及其用途 | |
| CN114402075A (zh) | 乌谢尔综合征(ush2a)的基因疗法 | |
| HK40106592A (en) | Gene therapy methods for age-related diseases and conditions | |
| CN116323941A (zh) | 通过诱导抗肌萎缩蛋白相关蛋白调节元件内的突变增强细胞中抗肌萎缩蛋白相关蛋白表达及其治疗用途 | |
| EP3784290A1 (en) | Aav capsids identified by in vivo library selection | |
| WO2024097521A2 (en) | Compositions for treatment of osteogenesis imperfecta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200522 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200717 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220805 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220805 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220920 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221011 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221018 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221111 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241016 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250129 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7632835 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |